BSTG News

Biostage, which is developing an esophageal implant using stem cell technology, withdrew its plans for an initial public offering on Wednesday. It originally filed in June 2022 with a proposed deal size of $12 million. The company is currently listed on the OTC (BSTG). ...read more

Biostage, which is developing an esophageal implant using stem cell technology, filed on Tuesday with the SEC to raise up to $12 million in a Nasdaq uplisting. The company is thinly traded on the OTCQB under the symbol BSTG.  Biostage states that it is initially targeting regeneration of the organs of the gastro-intestinal tract and the airway, where organ transplants are not...read more